Treatment

Safety results of the Phase III gantenerumab GRADUATE I and II studies

Improving the next generation of anti-amyloid antibodies: prioritizing selectivity with PMN310

Symptomatic versus disease modifying treatments

Defining subgroups of patients with subjective cognitive decline more likely to progress

European task force recommendations: shifting memory clinics towards prevention

Distinguishing between disease modifying and symptomatic effects in clinical trials

Phase II trial of AR1001 as a potential treatment for Alzheimer’s disease

Past and future of immunotherapy in Alzheimer’s disease

Gotcha! A therapy app for proper name anomia in dementia

Lecanemab: drawbacks to consider

Lecanemab: a review

FDA approval of lecanemab: what does the data tell us about the amyloid hypothesis?

Lecanemab vs aducanumab

Targeting the pancreas to treat Alzheimer’s disease

Diabetes-associated cognitive dysfunction

New pivotal study using photobiomodulation in Alzheimer’s treatment